ArticleGenome medicine2025
PathHDNN: a pathway hierarchical-informed deep neural network framework for predicting immunotherapy response and mechanism interpretation.
Article in Genome medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- TF-GateNet: An Interpretable and Biologically Guided Framework for Primary-Metastatic State Prediction from Somatic Genomic Alterations.Biomolecules · 2026Article
- ICIsc: A Deep Learning Framework for Predicting Immune Checkpoint Inhibitor Response by Integrating scRNA-Seq and Protein Language Models.Bioengineering (Basel, Switzerland) · 2026Article
- Anti-angiogenic therapy in thymic carcinoma: a narrative review of current evidence and emerging combinations.Mediastinum (Hong Kong, China) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundImmunotherapy has revolutionized the treatment of cancer and tremendously prolonged the overall survival of patients; however, only parts of patients could derive durable clinical benefit from it. Predicting clinical responses to immunotherapy and interpreting the response mechanism remain major challenges.
methodsHere, we presented a pathway hierarchical-informed deep neural network (PathHDNN) framework to predict the therapeutic responses of cancer patients and identify key pathways associated with immunotherapy efficacy. PathHDNN was trained by encoding established biological pathway hierarchically knowledge into a neural network architecture through embedding the somatic mutations and copy number variations. During training, PathHDNN optimized only the edge weights connecting hierarchically related pathways, while maintaining the fixed network topology derived from biological pathway hierarchy, thereby preserving biological interpretability throughout the learning process.
resultsWe assessed PathHDNN on multiple immunotherapy cohorts and found it outperformed other state-of-the-art machine learning methods and established immunotherapy biomarkers. Moreover, through interpreting the trained model, PathHDNN effectively identified critical pathway features associated with the therapeutic response in melanoma cohort, particularly noting the critical roles of p53-mediated tumor suppression and JAK2-mediated immune regulation in the course of responsiveness to immunotherapy.
conclusionsIn conclusion, PathHDNN provided an effective pathway hierarchical-informed framework for accurately predicting patient responses to immunotherapy and identified key pathways yielding valuable insights into the biological mechanisms underlying treatment responses, which is essential for advancing precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.